These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 28224237

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Remyelination in multiple sclerosis.
    Chari DM.
    Int Rev Neurobiol; 2007; 79():589-620. PubMed ID: 17531860
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis.
    Dulamea AO.
    Adv Exp Med Biol; 2017; 958():91-127. PubMed ID: 28093710
    [Abstract] [Full Text] [Related]

  • 26. Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination.
    Syed YA, Zhao C, Mahad D, Möbius W, Altmann F, Foss F, González GA, Sentürk A, Acker-Palmer A, Lubec G, Lilley K, Franklin RJM, Nave KA, Kotter MRN.
    Acta Neuropathol; 2016 Feb; 131(2):281-298. PubMed ID: 26687980
    [Abstract] [Full Text] [Related]

  • 27. The Molecular Basis for Remyelination Failure in Multiple Sclerosis.
    Gruchot J, Weyers V, Göttle P, Förster M, Hartung HP, Küry P, Kremer D.
    Cells; 2019 Aug 03; 8(8):. PubMed ID: 31382620
    [Abstract] [Full Text] [Related]

  • 28. Repair strategies for multiple sclerosis: challenges, achievements and perspectives.
    Stankoff B, Jadasz JJ, Hartung HP, Küry P, Zalc B, Lubetzki C.
    Curr Opin Neurol; 2016 Jun 03; 29(3):286-92. PubMed ID: 27035897
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Laquinimod Supports Remyelination in Non-Supportive Environments.
    Nyamoya S, Steinle J, Chrzanowski U, Kaye J, Schmitz C, Beyer C, Kipp M.
    Cells; 2019 Oct 31; 8(11):. PubMed ID: 31683658
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier?
    Tepavčević V, Lubetzki C.
    Brain; 2022 Dec 19; 145(12):4178-4192. PubMed ID: 36093726
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. G-Protein-Coupled Receptor Gpr17 Expression in Two Multiple Sclerosis Remyelination Models.
    Nyamoya S, Leopold P, Becker B, Beyer C, Hustadt F, Schmitz C, Michel A, Kipp M.
    Mol Neurobiol; 2019 Feb 19; 56(2):1109-1123. PubMed ID: 29873041
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
    Pan S, Chan JR.
    Ann Neurol; 2021 Oct 19; 90(4):558-567. PubMed ID: 34402546
    [Abstract] [Full Text] [Related]

  • 37. Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.
    Stangel M, Trebst C.
    Curr Neurol Neurosci Rep; 2006 May 19; 6(3):229-35. PubMed ID: 16635432
    [Abstract] [Full Text] [Related]

  • 38. The remyelination Philosopher's Stone: stem and progenitor cell therapies for multiple sclerosis.
    Jadasz JJ, Aigner L, Rivera FJ, Küry P.
    Cell Tissue Res; 2012 Jul 19; 349(1):331-47. PubMed ID: 22322424
    [Abstract] [Full Text] [Related]

  • 39. MicroRNAs in oligodendrocyte development and remyelination.
    Ngo C, Kothary R.
    J Neurochem; 2022 Aug 19; 162(4):310-321. PubMed ID: 35536759
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.